acib has been involved in CHO cell genomic research from the beginning, including generation of a reference genome within an International consortium (https://chogenome.org/). Using transcript-tomics, proteomics, metabolomics and noncoding RNA-omics, acib can characterize newly generated subclones or cell lines under different process conditions. This information is used to streamline CLD or optimise processes, supported by computational predictions using a genome-scale metabolic model. We also offer tools for targeted engineering approaches, e.g. CRISPR/Cas9 based targeted integration into predicted hot spots or modulation of gene expression levels by epigenetic engineering. Combined, acib’s expertise provides industrial partners with a deeper understanding of the limitations of their specific system with respect to productivity, growth and product quality, while also providing strategies to overcome these, to achieve reduced time to market and lower production costs.
Experts:Prof. Dr. Nicole Borth, Dr. Martina Baumann
Investments, Joint Research Projects, Contract Research
Status of the project proposal:
Readiness Level 1-5
IPR:Will be generated for our industrial partner / investor
Keywords:CHO-Cells, Therapeutic Proteins, Production Cell Line, Reference Genome, Epigenetics, Metabolic Model, Cell Engineering, Reliability, Stability, Productivity
Picture credits: Pixabay